Mature B-Cell Non-Hodgkin Lymphoma — Research

Mature B-Cell Non-Hodgkin Lymphoma — Research · CancerIndex

Research activity

PubMed record counts

Each count is the number of PubMed records returned by the exact query shown, at the time it was run. Counts are research-activity signals, not quality measures.

pubmedComputed14 windows · counts computed by CancerIndex from PubMed E-utilities; the exact query is stored with each count.

Window	Period	Records (count)	Exact query	Computed	Source
All time	… → 2026-09-29	326	`("Mature B-Cell Non-Hodgkin Lymphoma"[tiab] OR "Mature B-Cell Lymphoma"[tiab] OR "Mature B-Cell Non-Hodgkin's Lymphoma"[tiab])`	2026-09-29	pubmed
Last 5 years	2021-01-01 → 2026-12-31	143	`("Mature B-Cell Non-Hodgkin Lymphoma"[tiab] OR "Mature B-Cell Lymphoma"[tiab] OR "Mature B-Cell Non-Hodgkin's Lymphoma"[tiab]) AND (2021/01/01:2026/12/31[dp])`	2026-09-29	pubmed
Preceding 5-year window	2020-09-29 → 2025-09-28	126	`("Mature B-Cell Non-Hodgkin Lymphoma"[tiab] OR "Mature B-Cell Lymphoma"[tiab] OR "Mature B-Cell Non-Hodgkin's Lymphoma"[tiab]) AND (2020/09/29:2025/09/28[dp])`	2026-09-29	pubmed
Last 12 months	2025-09-29 → 2026-09-29	26	`("Mature B-Cell Non-Hodgkin Lymphoma"[tiab] OR "Mature B-Cell Lymphoma"[tiab] OR "Mature B-Cell Non-Hodgkin's Lymphoma"[tiab]) AND (2025/09/29:2026/09/29[dp])`	2026-09-29	pubmed
y2016	2016-01-01 → 2016-12-31	18	`("Mature B-Cell Non-Hodgkin Lymphoma"[tiab] OR "Mature B-Cell Lymphoma"[tiab] OR "Mature B-Cell Non-Hodgkin's Lymphoma"[tiab]) AND (2016/01/01:2016/12/31[dp])`	2026-09-29	pubmed
y2017	2017-01-01 → 2017-12-31	13	`("Mature B-Cell Non-Hodgkin Lymphoma"[tiab] OR "Mature B-Cell Lymphoma"[tiab] OR "Mature B-Cell Non-Hodgkin's Lymphoma"[tiab]) AND (2017/01/01:2017/12/31[dp])`	2026-09-29	pubmed
y2018	2018-01-01 → 2018-12-31	14	`("Mature B-Cell Non-Hodgkin Lymphoma"[tiab] OR "Mature B-Cell Lymphoma"[tiab] OR "Mature B-Cell Non-Hodgkin's Lymphoma"[tiab]) AND (2018/01/01:2018/12/31[dp])`	2026-09-29	pubmed
y2019	2019-01-01 → 2019-12-31	27	`("Mature B-Cell Non-Hodgkin Lymphoma"[tiab] OR "Mature B-Cell Lymphoma"[tiab] OR "Mature B-Cell Non-Hodgkin's Lymphoma"[tiab]) AND (2019/01/01:2019/12/31[dp])`	2026-09-29	pubmed
y2020	2020-01-01 → 2020-12-31	31	`("Mature B-Cell Non-Hodgkin Lymphoma"[tiab] OR "Mature B-Cell Lymphoma"[tiab] OR "Mature B-Cell Non-Hodgkin's Lymphoma"[tiab]) AND (2020/01/01:2020/12/31[dp])`	2026-09-29	pubmed
y2021	2021-01-01 → 2021-12-31	19	`("Mature B-Cell Non-Hodgkin Lymphoma"[tiab] OR "Mature B-Cell Lymphoma"[tiab] OR "Mature B-Cell Non-Hodgkin's Lymphoma"[tiab]) AND (2021/01/01:2021/12/31[dp])`	2026-09-29	pubmed
y2022	2022-01-01 → 2022-12-31	26	`("Mature B-Cell Non-Hodgkin Lymphoma"[tiab] OR "Mature B-Cell Lymphoma"[tiab] OR "Mature B-Cell Non-Hodgkin's Lymphoma"[tiab]) AND (2022/01/01:2022/12/31[dp])`	2026-09-29	pubmed
y2023	2023-01-01 → 2023-12-31	35	`("Mature B-Cell Non-Hodgkin Lymphoma"[tiab] OR "Mature B-Cell Lymphoma"[tiab] OR "Mature B-Cell Non-Hodgkin's Lymphoma"[tiab]) AND (2023/01/01:2023/12/31[dp])`	2026-09-29	pubmed
y2024	2024-01-01 → 2024-12-31	26	`("Mature B-Cell Non-Hodgkin Lymphoma"[tiab] OR "Mature B-Cell Lymphoma"[tiab] OR "Mature B-Cell Non-Hodgkin's Lymphoma"[tiab]) AND (2024/01/01:2024/12/31[dp])`	2026-09-29	pubmed
y2025	2025-01-01 → 2025-12-31	38	`("Mature B-Cell Non-Hodgkin Lymphoma"[tiab] OR "Mature B-Cell Lymphoma"[tiab] OR "Mature B-Cell Non-Hodgkin's Lymphoma"[tiab]) AND (2025/01/01:2025/12/31[dp])`	2026-09-29	pubmed

Data updated 2 days agoSource updated unknownsource: pubmed E-utilities

Literature

Linked publications (42)

Publications linked to this entity or its descendants, newest first, 25 per page. Link method and validation status are shown; 'candidate' links have not been reviewed.

pubmedPublishedShowing 26–42 of 42 publications · bibliographic data as recorded by PubMed; abstracts are not reproduced.

Phase 1 study of tazemetostat in Japanese patients with relapsed or refractory B-cell lymphoma.
· Cancer Sci · 2021 · PMID 33492746 · validated civic_curation pubmed
Inhibition of anaplastic lymphoma kinase (ALK) activity provides a therapeutic approach for CLTC-ALK-positive human diffuse large B cell lymphomas.
· PLoS One · 2011 · PMID 21494621 · validated civic_curation pubmed
Selective inhibition of Ezh2 by a small molecule inhibitor blocks tumor cells proliferation.
· Proc Natl Acad Sci U S A · 2012 · PMID 23236167 · validated civic_curation pubmed
The EMT activator ZEB1 promotes tumor growth and determines differential response to chemotherapy in mantle cell lymphoma.